Delving into the Latest Updates on DWP-17061 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DWP 17061, DWP-17061, IN1011 N17

+ [1]

Target

Nav1.7

Mechanism

Nav1.7 blockers(Sodium channel protein type IX alpha subunit blockers)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Arthritis PainChronic PainNeuralgia, Postherpetic+ [1]

Inactive Indication

Musculoskeletal Pain

Originator Organization

Daewoong Pharmaceutical Co., Ltd.

Active Organization

In Therapeutics Co. Ltd.Startup

Inactive Organization

Daewoong Pharmaceutical Co., Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers

This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia patients, and to assess the relative bioavailability of Mesylate vs Hydrochloride salt capsules of iN1011-N17 in Healthy volunteers.

Start Date11 Nov 2022

Sponsor / Collaborator

In Therapeutics Co. Ltd.Startup

ACTRN12622001300763 / RecruitingPhase 1

A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers

Start Date24 Aug 2022

Sponsor / Collaborator

In Therapeutics Co. Ltd.Startup

ACTRN12620001253998 / RecruitingPhase 1

A randomized, double-blind, placebo-controlled, single-ascending dose Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics properties of iN1011N17 after oral administration in healthy volunteers

Start Date16 Nov 2020

Sponsor / Collaborator

In Therapeutics Co. Ltd.Startup

100 Clinical Results associated with DWP-17061

Login to view more data

100 Translational Medicine associated with DWP-17061

Login to view more data

100 Patents (Medical) associated with DWP-17061

Login to view more data

100 Deals associated with DWP-17061

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthritis Pain	Phase 1	KR	In Therapeutics Co. Ltd.Startup	26 Apr 2023
Chronic Pain	Phase 1	AU	In Therapeutics Co. Ltd.Startup	30 Sep 2020
Neuralgia, Postherpetic	Phase 1	AU	In Therapeutics Co. Ltd.Startup	30 Sep 2020
Osteoarthritis	Phase 1	AU	In Therapeutics Co. Ltd.Startup	30 Sep 2020
Musculoskeletal Pain	Phase 1	AU	Daewoong Pharmaceutical Co., Ltd.	29 Sep 2020